Researchers have unveiled a way to flip genes back on without slicing into the genome, a shift that could make CRISPR far safer and more flexible. Instead of cutting DNA, the new approach scrubs away ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

CRISPR-Cas systems are adaptive immune systems found in prokaryotes that defend against invading nucleic acids through CRISPR RNA-guided cleavage. Type V CRISPR-Cas (Cas12) systems, in particular, ...

CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...

CRISPR gene-editing has improved the vision of patients with an inherited form of blindness, according to results of a Phase 1/2 clinical trial. The results not only give new hope to patients with the ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...